Vaccination In Peripheral Stem Cell Transplant Setting For Multiple Myeloma: The Use Of Autologous Tumor Cells/An Allo PSCT
- Determine the efficacy of induction chemotherapy followed by autologous tumor cell
vaccine and autologous peripheral blood stem cell transplantation in patients with
- Determine the safety of this regimen in these patients.
OUTLINE: Autologous tumor cells are harvested. The vaccine is prepared in vitro by mixing
autologous tumor cells with a bystander cell expressing sargramostim (GM-CSF). Patients
receive induction chemotherapy followed by autologous tumor cell vaccination (ATCV) once.
Patients then undergo autologous peripheral blood stem cell transplantation. At 6 weeks
after transplantation, patients receive additional ATCVs every 3 weeks for a total of 8
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Primary Purpose: Treatment
Ivan Borrello, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|